Investors & Media

Company Statements

Company Statements

October 7, 2023
Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen
October 7, 2023
Ionis statement about results from an analysis of exploratory cardiac endpoints in the Phase 3 NEURO-TTRansform study of eplontersen
January 23, 2023
Ionis’ statement about the FDA advisory committee meeting on tofersen